Navigation Links
First Patient Dosed with KX2-391 in Phase 1 Clinical Trial
Date:11/27/2007

BUFFALO, N.Y., Nov. 27 /PRNewswire/ -- Kinex Pharmaceuticals LLC, announced today that their drug KX2-391 (KX01) has begun Phase 1 human testing. The study is entitled "A combined rising single-dose (RSD) and rising multiple-dose (RMD) Phase 1 study to evaluate safety, tolerability and pharmacokinetics of KX2-391 in patients with advanced malignancies that are refractory to conventional therapies". The drug belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors.

Dosing has begun at Roswell Park Cancer Institute in Buffalo, N.Y., and will commence in the next several days at M.D. Anderson Cancer Center in Houston, Texas. The trial is expected to enroll 50 patients with advanced solid tumors and lymphoma and will evaluate safety, tolerability and pharmacokinetics. Exploratory biomarker studies will also be involved.

"What's remarkable about this compound is that, in preclinical testing, it has worked against every cancer and in every animal model," said David Hangauer, a University at Buffalo chemistry professor whose work was integral to the drug's creation. Hangauer is a co-founder of Kinex and serves as the Company's Senior Vice President of Research and Development. KX2-391 targets an important cell signaler called Src kinase, a protein linked to the rapid growth and spread of cancer cells. A potential advantage of Kinex's kinase inhibitor is that it disrupts Src at a site different from where other currently studied compounds are targeted, reducing the chance that patients will develop resistance to the new drug, Hangauer said.

"As we go further in the drug's development, and do broader testing, we get better and better data," said Allen Barnett, Chief Executive Officer of Kinex Pharmaceuticals. "We are extremely enthusiastic about the potential for KX2-391 because it represents a unique approach for the treatment of cancer. It is a first-in-class drug that has the potential to provide patients
'/>"/>

SOURCE Kinex Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  A mere one ... Booz Allen Hamilton . A new white ... development inefficiencies are impeding and disrupting manufacturers, success. ... Waste and Improve Value In Product Development Processes ... inaccessible data and how it affects the product development ...
(Date:8/27/2015)... , Aug. 27, 2015 NorthStar Anesthesia ... today that it has been selected by Mercy, based in ... services for four of their hospitals:  Mercy St. Vincent  Medical ... Toledo , Mercy St. Charles  Hospital in ... Tiffin . "As we ...
(Date:8/27/2015)... -- According to a new market research ... by Deployment Mode (Web based, On-Premise, Cloud-Based), by End ... by Component - Global Trends & Forecast to 2019", ... $501.1 Million 2014, and is projected to reach $722.7 ... 2014 to 2019. Browse 60 T ...
Breaking Medicine Technology:New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2Four Mercy Hospitals in Northwest Ohio Select NorthStar Anesthesia 2Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 4
... March 24, 2011 A new program from American ... consumers regarding the price of advanced diagnostic imaging exams ... are performed, offering significant cost savings and increased satisfaction. ... care spending, there is a growing need for information ...
... PARSIPPANY, N.J., March 24, 2011 PDI, Inc. (Nasdaq: ... NASDAQ Stock Market Closing Bell on Tuesday, March 29, 2011, at ... PDI CEO Nancy Lurker will ring the Closing Bell together with ... "Ringing the NASDAQ bell is a particularly meaningful event for PDI ...
Cached Medicine Technology:American Imaging Management Promotes Affordability and Choice to Health Care Consumers 2American Imaging Management Promotes Affordability and Choice to Health Care Consumers 3American Imaging Management Promotes Affordability and Choice to Health Care Consumers 4
(Date:8/28/2015)... ... 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, a ... carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch that ... Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected by ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... specialist, Dr. James Strawbridge, gives a new approach on solutions in his new ... with the employer and employees getting together for meaningful group meetings. "This would ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... three-year accreditation for its adolescent residential, counseling, day treatment and intensive family based ... meets international standards for quality and its pursuit of excellence. As a nonprofit ...
(Date:8/28/2015)... NY (PRWEB) , ... August 28, 2015 , ... The ... Kybella™. It is the first and only nonsurgical product approved by the Food ... Dr. Vito Quatela and Dr. William Koenig are among the ...
(Date:8/28/2015)... ... 2015 , ... SharkNinja, an innovative leader in the housewares ... Sofia Vergara, and unveil the Ninja® brand’s new coffee machine, the Ninja ... variety of sizes and styles while achieving the perfect brew richness level every ...
Breaking Medicine News(10 mins):Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3
... EAST LANSING, Mich., Oct. 25 The Board of,Directors ... ),has declared a cash dividend of 10 cents per ... at the close of business on December 13,2007. At ... Corporate Description American Physicians Capital, Inc. is ...
... Calif., Oct. 25 Thoratec,Corporation (Nasdaq: THOR ), ... announced that it will report its operating,results for the ... The company will hold a conference call to ... interested parties at 8:30,a.m., Pacific Daylight Time (11:30 a.m., ...
... tensor imaging can identify structural changes in the white ... even in patients with mild traumatic brain injury. ... of the journal Brain. , "We studied patients ... to severe -- and found that abnormalities in white ...
... Vessel Road Mapping and Magnetic Guidewire Navigation ... Capabilities Demonstrated in Multiple Cases, ST. ... the details of successful, live percutaneous coronary,and peripheral cases ... the Main Arena at the Transcatheter Cardiovascular,Therapeutics (TCT) symposium, ...
... USO has,partnered with CarePages.com to provide wounded troops an ... friends while recovering,in the hospital and at home. Called ... sharing health updates, photos and supportive,messages via a private ... care and support, and allows them to share updates ...
... drugs of tomorrow and how will they be ... Molecular Targets and Cancer Therapeutics, researchers will present ... regarding emerging cancer therapeutics. , New ... cancer tumors, provide tantalizing targets for engineered antibodies ...
Cached Medicine News:Health News:Thoratec Schedules Third Quarter Conference Call, Webcast 2Health News:Imaging shows structural changes in mild traumatic brain injury 2Health News:Imaging shows structural changes in mild traumatic brain injury 3Health News:Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System 2Health News:Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System 3Health News:Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System 4Health News:The USO and CarePages.com Help Wounded Troops Stay Connected to Their Families 2Health News:The USO and CarePages.com Help Wounded Troops Stay Connected to Their Families 3Health News:Targets on the horizon: Emerging therapies and novel targets 2Health News:Targets on the horizon: Emerging therapies and novel targets 3Health News:Targets on the horizon: Emerging therapies and novel targets 4Health News:Targets on the horizon: Emerging therapies and novel targets 5Health News:Targets on the horizon: Emerging therapies and novel targets 6Health News:Targets on the horizon: Emerging therapies and novel targets 7
... camera incorporates a Progressive Scan 1/3" CCD with ... x 768 (V) XGA. Whats more the XCD-X710CR ... called a "Bayer filter") and outputs the "raw ... to be converted to a color image on ...
... Sonys XCD-X710 digital camera incorporates a Progressive ... offers excellent sensitivity (1024 x 768 XGA ... high-resolution, digital B/W images and features an ... exposure range from 1/100,000 to 17.5 second, ...
... The PL-A661 is a monochrome " 1.3 ... microscopy applications. Desgined to simplify real-time ... the PL-A661 provides uncompromising video and digital ... package. The PL-A661 is ideal for industrial ...
... FireWire, high dynamics. Exceptional performance in the ... for your applications: The possibility to respond ... and laboratory work, meeting new challenges with ... been combined with so much flexibility in ...
Medicine Products: